Skip to content
10-Q

Quarterly Report

VIKING THERAPEUTICS, INC. VKTX

0000950170-25-058129

← back to feed
Filed
Apr 24, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 15, 2025 112.31M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $37.94M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $26.68M
Stockholders Equity Q1 2025 · Mar 31, 2025 $846.92M
Stockholders Equity Q1 2025 · Dec 31, 2024 $880.28M
Current Liabilities Q1 2025 · Mar 31, 2025 $19.57M
Current Liabilities Q1 2025 · Dec 31, 2024 $27.41M
Total Liabilities Q1 2025 · Mar 31, 2025 $20.08M
Total Liabilities Q1 2025 · Dec 31, 2024 $28.04M
Current Assets Q1 2025 · Mar 31, 2025 $866.02M
Current Assets Q1 2025 · Dec 31, 2024 $907.22M
Total Assets Q1 2025 · Mar 31, 2025 $866.99M
Total Assets Q1 2025 · Dec 31, 2024 $908.32M
Shares Diluted Q1 2025 · Mar 31, 2024 103.46M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$6.13M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.26
Eps Basic Q1 2025 · Mar 31, 2024 −$0.26
Sga Expense Q1 2025 · Mar 31, 2024 $9.97M
Rd Expense Q1 2025 · Mar 31, 2024 $24.1M
Net Income Q1 2025 · Mar 31, 2024 −$27.36M
Operating Income Q1 2025 · Mar 31, 2024 −$34.07M
Revenue Q1 2025 · Mar 31, 2024 $0